Ankylosing spondylitis
Conference Coverage
Are women and men with rheumatism treated equally?
Compared with men, women receive a diagnosis of rheumatic disease much later and are treated more poorly, research suggests.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
From the Journals
Mortality in ankylosing spondylitis: CV disease, drug abuse are big contributors
Heart failure and renal disease were the strongest contributing comorbidities to mortality in hospitalized patients with ankylosing spondylitis....
From the Journals
Fracture risk factors described in patients with ankylosing spondylitis
Individuals with a history of fracture were five times more likely to develop an additional fracture.
Latest News
Rheumatology trials seem vulnerable to unblinding: Report
In an analysis of 14 published randomized controlled clinical trials of common rheumatology drugs, most had a high estimated risk for inadvertent...
Conference Coverage
Structural changes may separate axial psoriatic arthritis from axial spondyloarthritis
Approximately two-thirds of patients met criteria for both conditions, but imaging data show distinctions.
From the Journals
Spondyloarthritis-related diseases share gut microbiota dysbiosis
Stool samples from patients with spondyloarthritis, acute anterior uveitis, and/or Crohn’s disease showed similarly low levels of certain bacteria...
From the Journals
Could risk stratifying methotrexate users lead to less frequent testing?
A new prognostic model accurately predicts a patient’s risk of experiencing methotrexate toxicity, but more research is needed before clinical...
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
Feature
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...